Plasminogen activator inhibitor 1 promotes aortic aging–like pathophysiology in humans and mice
Authors:
- Alireza KhoddamAKAlireza Khoddam
- Anthony KalousdianAKAnthony Kalousdian
- Mesut ErenMEMesut Eren
- Saul SoberanesSSSaul Soberanes
- Andrew DeckerADAndrew Decker
- Elizabeth J. LuxELElizabeth J. Lux
- Benjamin W. ZywickiBZBenjamin W. Zywicki
- Brian DinhBDBrian Dinh
- Bedirhan BoztepeBBBedirhan Boztepe
- Baljash S. CheemaBCBaljash S. Cheema
- Carla M. CudaCCCarla M. Cuda
- Hiam Abdala-ValenciaHiam Abdala-Valencia
Open Access
- 30 September 2025
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (23)
Abstract
Plasminogen activator inhibitor 1 (PAI-1), encoded by SERPINE1 , contributes to age-related cardiovascular disease (CVD) and other aging-related pathologies. Humans with a heterozygous loss-of-function SERPINE1 variant exhibit protection against aging and cardiometabolic dysfunction. We engineered a mouse model mimicking the human mutation ( Serpine1 TA700/+ ) and compared cardiovascular responses with WT littermates. Serpine1 TA700/+ mice lived 17% longer than did littermate control mice. Under l-N G -nitro-arginine methyl ester–induced (l-NAME–induced) vascular stress, Serpine1 TA700/+ mice exhibited diminished pulse wave velocity (PWV), lower systolic blood pressure (SBP), and preserved left ventricular diastolic function compared with controls. Conversely, PAI-1–overexpressing mice had measurements indicating accelerated cardiovascular aging. Single-cell transcriptomics of Serpine1 TA700/+ aortas revealed a vascular-protective mechanism with downregulation of the extracellular matrix regulators Ccn1 and Itgb1 . Serpine1 TA700/+ aortas were also enriched in a cluster of smooth muscle cells that exhibited plasticity. Finally, PAI-1 pharmacological inhibition normalized SBP and reversed l-NAME–induced PWV elevation. These findings demonstrate that PAI-1 reduction protects against cardiovascular aging-related phenotypes, while PAI-1 excess promotes vascular pathological changes. Taken together, PAI-1 inhibition represents a promising strategy to mitigate age-related CVD.Keywords
Funding Information
- NIH Office of the Director (R01AI170938)
- American Heart Association (25PRE1356859)
- Norges Idrettshøgskole (R35HL171553)
- NIH Office of the Director (R35HL171553)
This publication has 77 references indexed in Scilit:
- Age-Dependent Spontaneous Coronary Arterial Thrombosis in Transgenic Mice That Express a Stable Form of Human Plasminogen Activator Inhibitor-1Circulation, 2002
- Potential Roles of Plasminogen Activator System in Coronary Vascular Remodeling Induced by Long-term Nitric Oxide Synthase InhibitionJournal of Molecular and Cellular Cardiology, 2002
- Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 DiabetesDiabetes, 2002
- High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and WomenCirculation, 1998
- Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.1997
- Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistanceBlood, 1996
- L-NAME Hypertension Alters Endothelial and Smooth Muscle Function in Rat AortaHypertension, 1995
- Nitric Oxide–Generating Compounds Inhibit Total Protein and Collagen Synthesis in Cultured Vascular Smooth Muscle CellsCirculation Research, 1995
- Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985